STAMPEDE

Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy

What is the best treatment for people with advanced prostate cancer?

What is this study about?

Prostate cancer accounts for around one-fifth of all male cancers. In the UK, there are ~47,000 new cases each year and ~11,000 deaths.

The STAMPEDE clinical trial aims to provide evidence on what is the best way of treating men with advanced prostate cancer.

Since 2005, almost 12,000 participants joined the trial. We have already reported practice-changing results that show adding docetaxel or abiraterone improves disease control and life expectancy. Several other treatments have been tested, including the results of abiraterone and enzalutamide combination and radiotherapy to the prostate in men with newly diagnosed metastatic disease. More recent results have shown that the addition of metformin to hormone therapy for prostate cancer can improve the side-effect profile of long-term treatment. The final part of the trial will be investigating whether hormone patches can be substituted for hormone injections to avoid some of the side effects and achieve just as good disease control.

The STAMPEDE trial has now completed recruitment. The final day of patient randomisation was completed on 31st March 2023, and the trial will close follow-up in 2026.

Short films summarising the results so far:

2023: STAMPEDE abiraterone and abiraterone + enzalutamide comparisons - a follow-up
2018: STAMPEDE M1 radiotherapy comparison results
2017: STAMPEDE abiraterone results
2015: STAMPEDE docetaxel and zoledronic acid results

2023: STAMPEDE abiraterone and abiraterone + enzalutamide comparisons - a follow-up
(10min)

2018: STAMPEDE M1 radiotherapy comparison results

Summary (6:33 min)

Full length (12:13 min)

2017: STAMPEDE abiraterone results

Summary (6:21 min)

Full version (12:48 min)

2015: STAMPEDE docetaxel and zoledronic acid results

Summary for health workers (14:08 min)

Summary for patients (14:56 min)

Type of study

Randomised trial

Contact details

mrcctu.stampede@ucl.ac.uk

Who is funding the study?

The trial is mainly funded by the charity Cancer Research UK with extra support from four pharmaceutical companies: Pfizer, Sanofi-Aventis, Novartis, Janssen, Astellas and Clovis.

When is it taking place?

The first STAMPEDE arms opened in 2005. Recruitment closed at the end of March 2023, and no further arms will be added to the study. Follow-up of enrolled patients continues.

Where is it taking place?

Follow up continues at participating hospitals in the UK. The participating Swiss sites are now closed and are no longer involved in the follow up or recruitment of participants.